Trospium: all 48 studies that test it

Page 1 of 1. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.

• Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaRecruitingNCT07686263Phase 3
• A PET/MRI Study of Cobenfy on Dopamine Transmission in SchizophreniaRecruitingNCT07423546Phase 1/2
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)RecruitingNCT07288567Phase 3
• A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum DisorderNot yet recruitingNCT07285798Phase 3
• A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With AutismNot yet recruitingNCT07284745Phase 3
• A Study to Evaluate the Effect of KarXT on Urological SafetyRecruitingNCT07221877Phase 4
• A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult ParticipantsRecruitingNCT07204418Phase 1
• A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or LamotrigineRecruitingNCT07140913Phase 3
• A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With SchizophreniaNot yet recruitingNCT07084831Phase 3
• A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending DosesRecruitingNCT07063342Phase 1
• A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXTRecruitingNCT07061288Phase 1
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseRecruitingNCT07011745Phase 3
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RecruitingNCT07011732Phase 3
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseRecruitingNCT06976216Phase 3
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)RecruitingNCT06976203Phase 3
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)RecruitingNCT06951711Phase 3
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderRecruitingNCT06951698Phase 3
• A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)RecruitingNCT06947941Phase 3
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)RecruitingNCT06937229Phase 3
• A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)RecruitingNCT06929273Phase 3
• An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With SchizophreniaNot yet recruitingNCT06924255Phase 4
• An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia PatientsNot yet recruitingNCT06923891Phase 4
• A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With SchizophreniaRecruitingNCT06882785Phase 3
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)RecruitingNCT06585787Phase 3
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)RecruitingNCT06126224Phase 3
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RecruitingNCT05980949Phase 3
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)RecruitingNCT05511363Phase 3
• Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With SchizophreniaCompletedNCT06572449Phase 3Results posted
• A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 SchizophreniaCompletedNCT05919823Phase 3Results posted
• An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of SchizophreniaTerminatedNCT05643170Phase 3Results posted
• A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaCompletedNCT05145413Phase 3Results posted
• An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)CompletedNCT04820309Phase 3Results posted
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)CompletedNCT04738123Phase 3Results posted
• An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)CompletedNCT04659174Phase 3Results posted
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)CompletedNCT04659161Phase 3Results posted
• Investigation of Brain Mechanisms Involved in Urgency Urinary IncontinenceCompletedNCT04227184Phase 4Results posted
• A Study to Assess Safety and Efficacy of KarXT in Adult Patients With SchizophreniaCompletedNCT03697252Phase 2Results posted
• The Effect of Anticholinergics on Cognitive Function in the ElderlyCompletedNCT01922115Phase 4Results posted
• Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) TrialCompletedNCT01178827Phase 4Results posted
• Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) DailyCompletedNCT01089751Phase 4Results posted
• Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy SubjectsCompletedNCT00986401Phase 1Results posted
• Trospium Chloride XR in Obese Female Patients With Overactive BladderCompletedNCT00932022Phase 4Results posted
• Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) TrialCompletedNCT00863551Phase 4Results posted
• KarXT Concentrations in the Breast Milk and Plasma of Lactating FemalesCompletedNCT07257120Phase 4
• A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult ParticipantsCompletedNCT06605950Phase 1
• An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaCompletedNCT05304767Phase 3
• Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms:SuspendedNCT03709992Not applicable
• Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus TrospiumCompletedNCT02831231Phase 1

← Trospium overview